Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05467722 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543
A Phase 1 study, sponsored by Concert Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT05467722 is a Phase 1 study that has completed, run by Concert Pharmaceuticals. The registered enrollment target is 21 participants.
The verdict
NCT05467722, a Phase 1 study, has completed, sponsored by Concert Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This is an open-label, single-dose, single-period, parallel group designed study to determine the effect of mild and moderate hepatic impairment on the pharmacokinetics (PK) of CTP-543 and its major metabolites following administration of a single 12 mg oral dose of CTP-543.
Interventions
- DRUG CTP-543
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2022-06-01 |
| Est. Completion | 2022-09-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05467722
The ClinicalTrials.gov registry entry for NCT05467722 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Concert Pharmaceuticals, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CTP-543 is the first listed.
NCT05467722 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05467722 about?
NCT05467722 is a clinical study titled "Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543". This is an open-label, single-dose, single-period, parallel group designed study to determine the effect of mild and moderate hepatic impairment on the pharmacokinetics (PK) of CTP-543 and its major metabolites following administration of a single 12 mg oral dose of CTP-543.
What is the current status of trial NCT05467722?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2022-06-01. Estimated completion is 2022-09-21.
What interventions are being tested in trial NCT05467722?
The interventions under investigation include: CTP-543 (DRUG).
Who is sponsoring clinical trial NCT05467722?
This trial is sponsored by Concert Pharmaceuticals, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.